MDAI vs GMED vs SYK vs ISRG

For growth investors, Spectral AI, Inc.

(MDAI) is the stronger pick with 63. 8% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Globus Medical, Inc. (GMED) offers the better valuation at 19. 9x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Globus Medical, Inc. (GMED) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Globus Medical, Inc.

(GMED) is the cheapest at 19. 9x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Globus Medical, Inc. is actually cheaper at 16. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Globus Medical, Inc. wins at 0. 54x versus Intuitive Surgical, Inc. 's 1. 99x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -76. 3% for Spectral AI, Inc. (MDAI). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus MDAI's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Spectral AI, Inc. 's 1. 55β — meaning MDAI is approximately 196% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Spectral AI, Inc.

(MDAI) is pulling ahead at 63. 8% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -51. 8% for Spectral AI, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -22. 3% for MDAI. At the gross margin level — before operating expenses — GMED leads at 67. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Globus Medical, Inc. (GMED) is the more undervalued stock at a PEG of 0. 54x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Globus Medical, Inc. (GMED) trades at 16. 7x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 26. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMED: 41. 5% to $110. 29.

In this comparison, SYK (1.

2% yield) pays a dividend. MDAI, GMED, ISRG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Spectral AI, Inc. (MDAI) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, MDAI: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MDAI is a small-cap high-growth stock; GMED is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; ISRG is a mid-cap high-growth stock. SYK pays a dividend while MDAI, GMED, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.